The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: A preliminary report

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 325-328

  Krysiak, Robert ^a   Okopien, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cytokines; Fenofibrate; Impaired fasting glucose; Impaired glucose tolerance; Lymphocytes; Systemic inflammation

Indexed keywords

CHOLESTEROL; CYTOKINE; FENOFIBRATE; GAMMA INTERFERON; GLUCOSE; INSULIN; INTERLEUKIN 2; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LIPID METABOLISM; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ATHEROSCLEROSIS; CYTOKINES; FEMALE; FENOFIBRATE; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOLIPIDEMIC AGENTS; LYMPHOCYTES; MALE; MIDDLE AGED; PLACEBOS; T-LYMPHOCYTES;

EID: 77958465400     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.07.016     Document Type: Article

References (17)

1. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
2. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37-45.
3. Balakumar P., Rose M., Singh M. PPAR ligands: are they potential agents for cardiovascular disorders?. Pharmacology 2007, 80:1-10.
4. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007, 67:121-153.
5. Krysiak R., Labuzek K., Okopien B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep 2009, 60:1134-1145.
6. Goldenberg I., Benderly M., Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manage 2008, 4:131-141.
7. Twigg S.M., Kamp M.C., Davis T.M., Neylon E.K., Flack J.R. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007, 186:461-465. Australian Diabetes Society; Australian Diabetes Educators Association.
8. Petersen J.L., McGuire D.K. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005, 2:9-15.
9. Okopien B., Krysiak R., Herman Z.S. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006, 91:1770-1778.
10. Krysiak R., Stachura-Kulach A., Okopien B. Metabolic and monocyte-suppressing action of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism abnormalities. Pharmacol Rep 2010, 62:127-137.
11. Okopien B., Krysiak R., Kowalski J., et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004, 176:327-335.
12. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
13. Weyand C.M., Younge B.R., Goronzy J.J. T cells in arteritis and atherosclerosis. Curr Opin Lipidol 2008, 19:469-477.
14. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007, 65(12 Pt 2):S253-S259.
15. Vakkilainen J., Steiner G., Ansquer J.C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107:1733-1737.
16. Sacks F.M. After the fenofibrate and event lowering in diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol 2008, 102:34L-40L.
17. Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. ACCORD Study Group.